MA71370A - Inhibiteurs macrocycliques de kras pour le traitement du cancer - Google Patents

Inhibiteurs macrocycliques de kras pour le traitement du cancer

Info

Publication number
MA71370A
MA71370A MA71370A MA71370A MA71370A MA 71370 A MA71370 A MA 71370A MA 71370 A MA71370 A MA 71370A MA 71370 A MA71370 A MA 71370A MA 71370 A MA71370 A MA 71370A
Authority
MA
Morocco
Prior art keywords
macrocyclic
cancer
treatment
kras inhibitors
kras
Prior art date
Application number
MA71370A
Other languages
English (en)
Inventor
Haixia Liu
Hong Shen
Weixing Zhang
Wei Zhu
Jianguo Chen
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA71370A publication Critical patent/MA71370A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA71370A 2022-07-04 2023-07-03 Inhibiteurs macrocycliques de kras pour le traitement du cancer MA71370A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2022103694 2022-07-04
CN2022124638 2022-10-11
CN2023070765 2023-01-05
CN2023087633 2023-04-11
PCT/EP2023/068154 WO2024008610A1 (fr) 2022-07-04 2023-07-03 Inhibiteurs macrocycliques de kras pour le traitement du cancer
EP23738471.4A EP4551578A1 (fr) 2022-07-04 2023-07-03 Inhibiteurs macrocycliques de kras pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA71370A true MA71370A (fr) 2025-04-30

Family

ID=87155635

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71370A MA71370A (fr) 2022-07-04 2023-07-03 Inhibiteurs macrocycliques de kras pour le traitement du cancer

Country Status (17)

Country Link
US (1) US20250257075A1 (fr)
EP (1) EP4551578A1 (fr)
JP (1) JP2025522629A (fr)
KR (1) KR20250029239A (fr)
CN (1) CN119546612A (fr)
AR (1) AR129819A1 (fr)
AU (1) AU2023303814A1 (fr)
CA (1) CA3261042A1 (fr)
CL (1) CL2024004085A1 (fr)
CO (1) CO2024017733A2 (fr)
CR (1) CR20240563A (fr)
IL (1) IL316867A (fr)
MA (1) MA71370A (fr)
MX (1) MX2024015363A (fr)
PE (1) PE20250843A1 (fr)
TW (1) TW202408507A (fr)
WO (1) WO2024008610A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4596552A1 (fr) 2022-09-29 2025-08-06 Guangzhou Joyo Pharmatech Co., Ltd Dérivé macrocyclique et son utilisation
PE20252395A1 (es) 2023-02-14 2025-10-10 Hoffmann La Roche Compuestos triciclicos para el tratamiento de cancer
WO2024211712A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025217307A1 (fr) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Procédés de prédiction de la réponse à un inhibiteur de ras(on) et polythérapies
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026021499A1 (fr) * 2024-07-24 2026-01-29 苏州泽璟生物制药股份有限公司 Inhibiteur cycloalkyle ou hétérocyclique substitué par haloalkylène, son procédé de préparation et son utilisation
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
WO2026035945A1 (fr) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Conjugués médicamenteux induits par covalence ciblant kras et comprenant une charge utile de topoisomérase
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026064520A1 (fr) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Conjugués médicamenteux à induction covalente ciblant kras et comprenant une charge utile inhibitrice de tubuline
WO2026064527A1 (fr) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Conjugués médicamenteux à induction covalente ciblant kras comprenant une charge utile d'inhibiteur de tubuline
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
WO2026106912A1 (fr) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026112260A1 (fr) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026122764A2 (fr) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026128688A2 (fr) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026161839A1 (fr) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005359A (es) * 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
EP4208261A1 (fr) * 2020-09-03 2023-07-12 Revolution Medicines, Inc. Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2

Also Published As

Publication number Publication date
WO2024008610A1 (fr) 2024-01-11
KR20250029239A (ko) 2025-03-04
CA3261042A1 (fr) 2024-01-11
AU2023303814A1 (en) 2024-11-21
EP4551578A1 (fr) 2025-05-14
PE20250843A1 (es) 2025-03-21
CN119546612A (zh) 2025-02-28
AR129819A1 (es) 2024-10-02
TW202408507A (zh) 2024-03-01
CL2024004085A1 (es) 2025-03-21
JP2025522629A (ja) 2025-07-15
IL316867A (en) 2025-01-01
US20250257075A1 (en) 2025-08-14
CR20240563A (es) 2025-02-14
CO2024017733A2 (es) 2025-01-13
MX2024015363A (es) 2025-03-07

Similar Documents

Publication Publication Date Title
MA71325A (fr) Inhibiteur de kras g12c pour le traitement du cancer
IL316867A (en) Macrocyclic KRAS inhibitors for cancer treatment
MA55959A (fr) Dosage d'inhibiteur de kras pour le traitement de cancers
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
EP4242207A4 (fr) Inhibiteurs de kras pour le traitement de cancers
EP4467154A4 (fr) Médicament pour le traitement ou la prévention du cancer
MA71551A (fr) Composés macrocycles pour le traitement du cancer
MA56050A (fr) Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP4259147A4 (fr) Polythérapies pour le traitement du cancer
EP4100061A4 (fr) Polythérapies et biomarqueurs pour le traitement du cancer
EP3947460A4 (fr) Agents multispécifiques pour le traitement du cancer
EP4149547A4 (fr) Compositions et méthodes pour le traitement du cancer
EP4319750A4 (fr) Polythérapies pour le traitement du cancer
EP4229048A4 (fr) Acylsulfonamides substitués pour le traitement du cancer
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP4373525A4 (fr) Combinaisons de traitement pour le cancer
EP3968987A4 (fr) Méthodes et substances pour le traitement du cancer
MA55084A (fr) Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
IL316829A (en) Menin-MLL inhibitors for cancer treatment
MA71734A (fr) Composés pour le traitement du cancer